Eric Bouffet

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5665785/publications.pdf

Version: 2024-02-01

397 papers	20,834 citations	13099 68 h-index	12272 133 g-index
442 all docs	442 docs citations	442 times ranked	17909 citing authors

#	Article	IF	Citations
1	Medulloblastoma Comprises Four Distinct Molecular Variants. Journal of Clinical Oncology, 2011, 29, 1408-1414.	1.6	1,131
2	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	16.8	836
3	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	27.8	761
4	Novel mutations target distinct subgroups of medulloblastoma. Nature, 2012, 488, 43-48.	27.8	742
5	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. Journal of Clinical Oncology, 2016, 34, 2206-2211.	1.6	692
6	Comprehensive Analysis of Hypermutation in Human Cancer. Cell, 2017, 171, 1042-1056.e10.	28.9	596
7	Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncology, The, 2006, 7, 241-248.	10.7	547
8	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics, 2014, 46, 451-456.	21.4	525
9	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature, 2014, 506, 445-450.	27.8	521
10	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 2016, 131, 821-831.	7.7	478
11	Change in Neurocognitive Functioning After Treatment With Cranial Radiation in Childhood. Journal of Clinical Oncology, 2004, 22, 706-713.	1.6	349
12	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.	10.7	307
13	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nature Genetics, 2015, 47, 257-262.	21.4	306
14	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274
15	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica, 2017, 133, 5-12.	7.7	271
16	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	27.8	266
17	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	1.6	263
18	MRI Surrogates for Molecular Subgroups of Medulloblastoma. American Journal of Neuroradiology, 2014, 35, 1263-1269.	2.4	257

#	Article	IF	Citations
19	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. Journal of Clinical Oncology, 2018, 36, 1963-1972.	1.6	250
20	Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro-Oncology, 2012, 14, 790-797.	1.2	248
21	BRAF Mutation and CDKN2A Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma. Journal of Clinical Oncology, 2015, 33, 1015-1022.	1.6	244
22	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell, 2020, 37, 569-583.e5.	16.8	244
23	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology, 2017, 35, 2934-2941.	1.6	232
24	Pineal Parenchymal Tumors: A Correlation of Histological Features with Prognosis in 66 Cases. Brain Pathology, 2000, 10, 49-60.	4.1	213
25	Parenchymal pineal tumors: a clinicopathological study of 76 cases. International Journal of Radiation Oncology Biology Physics, 2000, 46, 959-968.	0.8	212
26	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nature Communications, 2019, 10, 4343.	12.8	200
27	Science and health for all children with cancer. Science, 2019, 363, 1182-1186.	12.6	200
28	Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma. Journal of Clinical Oncology, 2012, 30, 1358-1363.	1.6	198
29	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
30	Central nervous system atypical teratoid rhabdoid tumours: The Canadian Paediatric Brain Tumour Consortium experience. European Journal of Cancer, 2012, 48, 353-359.	2.8	186
31	Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortium. European Journal of Cancer, 2014, 50, 987-996.	2.8	180
32	Impact of Craniospinal Dose, Boost Volume, and Neurologic Complications on Intellectual Outcome in Patients With Medulloblastoma. Journal of Clinical Oncology, 2014, 32, 1760-1768.	1.6	177
33	Sustainable care for children with cancer: a Lancet Oncology Commission. Lancet Oncology, The, 2020, 21, e185-e224.	10.7	177
34	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature, 2018, 553, 101-105.	27.8	170
35	Intracranial ependymomas in children: A critical review of prognostic factors and a plea for cooperation. , 1998, 30, 319-329.		163
36	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160

#	Article	IF	Citations
37	Phase II Weekly Vinblastine for Chemotherapy-NaÃ¯ve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. Journal of Clinical Oncology, 2016, 34, 3537-3543.	1.6	157
38	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncology, The, 2015, 16, 569-582.	10.7	147
39	Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. Journal of Clinical Oncology, 2020, 38, 454-461.	1.6	143
40	Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study. Journal of Clinical Oncology, 2015, 33, 2464-2471.	1.6	136
41	Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro-Oncology, 2017, 19, 1542-1552.	1.2	130
42	Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutationâ€“Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. Clinical Cancer Research, 2019, 25, 7303-7311.	7.0	128
43	Pediatric low-grade gliomas: next biologically driven steps. Neuro-Oncology, 2018, 20, 160-173.	1.2	116
44	Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncology, The, 2020, 21, e305-e316.	10.7	115
45	Prognostic Factors in Children With Localized Malignant Nonseminomatous Germ Cell Tumors. Journal of Clinical Oncology, 1999, 17, 1212-1212.	1.6	114
46	The COVIDâ€19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOPâ€E, SIOPâ€PODC, IPSO, PROS, CCI, and St Jude Global. Pediatric Blood and Cancer, 2020, 67, e28409.	1.5	113
47	Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?. Neuro-Oncology, 2016, 18, 291-297.	1.2	112
48	Spatial heterogeneity in medulloblastoma. Nature Genetics, 2017, 49, 780-788.	21.4	112
49	Survival Benefit for Pediatric Patients With Recurrent Ependymoma Treated With Reirradiation. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1541-1548.	0.8	111
50	Clinical and treatment factors determining longâ€term outcomes for adult survivors of childhood lowâ€grade glioma: A populationâ€based study. Cancer, 2016, 122, 1261-1269.	4.1	109
51	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). Journal of Clinical Oncology, 2021, 39, 822-835.	1.6	106
52	Chemotherapy for intracranial ependymomas. Child's Nervous System, 1999, 15, 563-570.	1.1	104
53	Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Acta Neuropathologica Communications, 2016, 4, 93.	5.2	100
54	From childhood to adulthood: long-term outcome of medulloblastoma patients. The Institut Curie experience (1980â€“2000). Journal of Neuro-Oncology, 2009, 95, 271-279.	2.9	97

#	Article	IF	Citations
55	Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential Highâ€Dose Chemotherapy. Pediatric Blood and Cancer, 2016, 63, 1527-1534.	1.5	94
56	Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. Neuro-Oncology, 2017, 19, 1279-1280.	1.2	93
57	A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. BMC Cancer, 2019, 19, 1250.	2.6	93
58	Early advice on managing children with cancer during the COVIDâ€19 pandemic and a call for sharing experiences. Pediatric Blood and Cancer, 2020, 67, e28327.	1.5	93
59	Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncology, The, 2021, 22, 1416-1426.	10.7	93
60	Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome. European Journal of Cancer, 2015, 51, 977-983.	2.8	87
61	Limited-field radiation for bifocal germinoma. International Journal of Radiation Oncology Biology Physics, 2006, 65, 486-492.	0.8	86
62	Intracystic Therapies for Cystic Craniopharyngioma in Childhood. Frontiers in Endocrinology, 2012, 3, 39.	3.5	86
63	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
64	A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. Cell, 2018, 172, 1050-1062.e14.	28.9	85
65	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. Clinical Cancer Research, 2015, 21, 184-192.	7.0	84
66	Impact of telemedicine on pediatric neuro-oncology in a developing country: The Jordanian-Canadian experience. Pediatric Blood and Cancer, 2007, 48, 39-43.	1.5	83
67	Attitudes of parents toward the return of targeted and incidental genomic research findings in children. Genetics in Medicine, 2014, 16, 633-640.	2.4	82
68	Pattern of relapse and outcome of non-metastatic germinoma patients treated with chemotherapy and limited field radiation: the SFOP experience. Neuro-Oncology, 2010, 12, 1318-25.	1.2	77
69	Functional and neuropsychological late outcomes in posterior fossa tumors in children. Child's Nervous System, 2015, 31, 1877-1890.	1.1	76
70	Epidemiological survey of central nervous system germ cell tumors in Canadian children. Journal of Neuro-Oncology, 2007, 82, 289-295.	2.9	74
71	Pediatric low-grade gliomas: implications of the biologic era. Neuro-Oncology, 2017, 19, now209.	1.2	73
72	Exercise training for neural recovery in a restricted sample of pediatric brain tumor survivors: a controlled clinical trial with crossover of training versus no training. Neuro-Oncology, 2017, 19, now177.	1.2	73

#	Article	IF	Citations
73	Intellectual Outcome in Molecular Subgroups of Medulloblastoma. Journal of Clinical Oncology, 2016, 34, 4161-4170.	1.6	72
74	Basal ganglia germinoma in children with associated ipsilateral cerebral and brain stem hemiatrophy. Pediatric Radiology, 2006, 36, 325-330.	2.0	70
75	Supratentorial primitive neuroectodermal tumors: a Canadian pediatric brain tumor consortium report. Journal of Neuro-Oncology, 2008, 86, 101-108.	2.9	69
76	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell, 2019, 36, 51-67.e7.	16.8	69
77	An attempt to treat pediatric intracranial alphaFP and betaHCG secreting germ cell tumors with chemotherapy alone. SFOP experience with 18 cases. SociÃ©tÃ© FranÃ§aise d'Oncologie PÃ©diatrique. Journal of Neuro-Oncology, 1998, 37, 229-239.	2.9	65
78	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathologica, 2020, 139, 223-241.	7.7	65
79	Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin. Nature Medicine, 2020, 26, 1285-1294.	30.7	65
80	Outcomes of children with central nervous system germinoma treated with multi-agent chemotherapy followed by reduced radiation. Journal of Neuro-Oncology, 2016, 127, 173-180.	2.9	64
81	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell, 2021, 39, 1519-1530.e4.	16.8	64
82	Current therapy and the evolving molecular landscape of paediatric ependymoma. European Journal of Cancer, 2017, 70, 34-41.	2.8	63
83	Repairing the brain with physical exercise: Cortical thickness and brain volume increases in long-term pediatric brain tumor survivors in response to a structured exercise intervention. NeuroImage: Clinical, 2018, 18, 972-985.	2.7	63
84	A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutationâ€“Positive Solid Tumors. Clinical Cancer Research, 2019, 25, 7294-7302.	7.0	63
85	Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro-Oncology, 2014, 16, 848-855.	1.2	62
86	High frequency of mismatch repair deficiency among pediatric high grade gliomas in <scp>J</scp>ordan. International Journal of Cancer, 2016, 138, 380-385.	5.1	62
87	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precision Oncology, 2020, 4, 561-571.	3.0	62
88	EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults. Neuro-Oncology, 2022, 24, 516-527.	1.2	60
89	Changes to Memory Structures in Children Treated for Posterior Fossa Tumors. Journal of the International Neuropsychological Society, 2014, 20, 168-180.	1.8	59
90	Profound clinical and radiological response to BRAF inhibition in a 2â€•monthâ€old diencephalic child with hypothalamic/chiasmatic glioma. Pediatric Blood and Cancer, 2016, 63, 2038-2041.	1.5	57

#	Article	IF	Citations
91	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine, 2022, 28, 125-135.	30.7	53
92	Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. Pediatric Blood and Cancer, 2018, 65, e26988.	1.5	51
93	White and Gray Matter Abnormalities After Cranial Radiation in Children and Mice. International Journal of Radiation Oncology Biology Physics, 2015, 93, 882-891.	0.8	50
94	Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. Cancer, 2019, 125, 1867-1876.	4.1	49
95	Closing the survival gap: Implementation of medulloblastoma protocols in a lowâ€income country through a twinning program. International Journal of Cancer, 2008, 122, 1203-1206.	5.1	47
96	Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma. British Journal of Cancer, 2008, 99, 1129-1135.	6.4	47
97	Salvage chemotherapy for metastatic and recurrent ependymoma of childhood. Child's Nervous System, 2009, 25, 1293-1301.	1.1	47
98	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	12.8	47
99	Consensus Report From the Stockholm Pediatric Proton Therapy Conference. International Journal of Radiation Oncology Biology Physics, 2016, 96, 387-392.	0.8	46
100	Survival Following Tumor Recurrence in Children With Medulloblastoma. Journal of Pediatric Hematology/Oncology, 2018, 40, e159-e163.	0.6	46
101	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro-Oncology, 2021, 23, 1360-1370.	1.2	46
102	DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells. Cancer Discovery, 2021, 11, 1176-1191.	9.4	46
103	Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro-Oncology, 2014, 16, 1554-1559.	1.2	44
104	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro-Oncology, 2020, 22, 773-784.	1.2	44
105	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. Acta Neuropathologica, 2021, 141, 771-785.	7.7	44
106	Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. Journal of Neuro-Oncology, 2017, 132, 155-162.	2.9	43
107	White matter and information processing speed following treatment with cranial-spinal radiation for pediatric brain tumor.. Neuropsychology, 2016, 30, 425-438.	1.3	42
108	Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Childrenâ€™s Oncology Group (ACNS1221). Journal of Clinical Oncology, 2020, 38, 223-231.	1.6	40

#	Article	IF	Citations
109	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
110	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. Journal of Clinical Oncology, 2021, 39, 2779-2790.	1.6	40
111	Executive function in paediatric medulloblastoma: The role of cerebrocerebellar connections. Journal of Neuropsychology, 2017, 11, 174-200.	1.4	39
112	Long-term visual outcomes of craniopharyngioma in children. Journal of Neuro-Oncology, 2018, 137, 645-651.	2.9	39
113	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro-Oncology, 2020, 22, 1474-1483.	1.2	39
114	Intracranial Germ Cell Tumors in Adolescents and Young Adults: A 40-Year Multi-Institutional Review of Outcomes. International Journal of Radiation Oncology Biology Physics, 2020, 106, 269-278.	0.8	38
115	Central nervous system metastasis in Wilms' tumor. Cancer, 1998, 83, 2023-2029.	4.1	37
116	White matter compromise predicts poor intellectual outcome in survivors of pediatric low-grade glioma. Neuro-Oncology, 2015, 17, 604-613.	1.2	36
117	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathologica, 2020, 139, 259-271.	7.7	36
118	Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clinical Cancer Research, 2021, 27, 2879-2889.	7.0	35
119	Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600â€“mutant pediatric low-grade glioma (pLGG).. Journal of Clinical Oncology, 2022, 40, LBA2002-LBA2002.	1.6	35
120	Challenges in management of patients with intracranial germ cell tumor and diabetes insipidus treated with cisplatin and/or ifosfamide based chemotherapy. Journal of Neuro-Oncology, 2010, 97, 393-399.	2.9	34
121	Possibilities of new therapeutic strategies in brain tumors. Cancer Treatment Reviews, 2010, 36, 335-341.	7.7	33
122	Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach. Journal of Neuro-Oncology, 2017, 133, 119-128.	2.9	32
123	Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. Neuro-Oncology, 2019, 21, 547-557.	1.2	32
124	Radiomics of Pediatric Low-Grade Gliomas: Toward a Pretherapeutic Differentiation of BRAF-Mutated and BRAF-Fused Tumors. American Journal of Neuroradiology, 2021, 42, 759-765.	2.4	32
125	The role of myeloablative chemotherapy with autologous hematopoietic cell rescue in central nervous system germ cell tumors. Pediatric Blood and Cancer, 2010, 54, 644-646.	1.5	31
126	Exercise training improves physical function and fitness in long-term paediatric brain tumour survivors treated with cranial irradiation. European Journal of Cancer, 2017, 80, 63-72.	2.8	31

#	Article	IF	Citations
127	Smaller hippocampal subfield volumes predict verbal associative memory in pediatric brain tumor survivors. Hippocampus, 2017, 27, 1140-1154.	1.9	30
128	Atypical teratoid rhabdoid tumor: molecular insights and translation to novel therapeutics. Journal of Neuro-Oncology, 2020, 150, 47-56.	2.9	30
129	Neurocognitive evaluation of long term survivors of atypical teratoid rhabdoid tumors (ATRT): The Canadian registry experience. Pediatric Blood and Cancer, 2015, 62, 1265-1269.	1.5	29
130	Management and outcome of chordomas in the pediatric population: The Hospital for Sick Children experience and review of the literature. Journal of Clinical Neuroscience, 2016, 34, 169-176.	1.5	29
131	Adolescents and young adults with brain tumors in the context of molecular advances in neuroâ€oncology. Pediatric Blood and Cancer, 2018, 65, e26861.	1.5	29
132	Supplementation of a Successful Pediatric Neuro-oncology Telemedicine-Based Twinning Program by E-Mails. Telemedicine Journal and E-Health, 2009, 15, 975-982.	2.8	27
133	Neoadjuvant chemotherapy reduces blood loss during the resection of pediatric choroid plexus carcinomas. Journal of Neurosurgery: Pediatrics, 2015, 16, 126-133.	1.3	27
134	The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. Journal of Neuro-Oncology, 2017, 132, 323-331.	2.9	27
135	LGG-46. TRAMETINIB THERAPY IN PEDIATRIC PATIENTS WITH LOW-GRADE GLIOMAS (LGG) WITH BRAF GENE FUSION; A DISEASE-SPECIFIC COHORT IN THE FIRST PEDIATRIC TESTING OF TRAMETINIB. Neuro-Oncology, 2018, 20, i114-i114.	1.2	27
136	Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAF V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST).. Journal of Clinical Oncology, 2015, 33, 10004-10004.	1.6	27
137	An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update. Child's Nervous System, 2016, 32, 1789-1797.	1.1	26
138	Parental spirituality in life-threatening pediatric cancer. Journal of Psychosocial Oncology, 2017, 35, 323-334.	1.2	26
139	Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency. Pediatric Blood and Cancer, 2018, 65, e27389.	1.5	25
140	Protocol: Evaluating the impact of a nation-wide train-the-trainer educational initiative to enhance the quality of palliative care for children with cancer. BMC Palliative Care, 2016, 15, 12.	1.8	24
141	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	6.5	24
142	Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. Journal of Clinical Oncology, 2019, 37, 461-470.	1.6	23
143	Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns. Acta Neuropathologica, 2020, 140, 765-776.	7.7	23
144	Visualization and segmentation of reciprocal cerebrocerebellar pathways in the healthy and injured brain. Human Brain Mapping, 2015, 36, 2615-2628.	3.6	22

#	Article	IF	Citations
145	Volumetric assessment of tumor size changes in pediatric low-grade gliomas: feasibility and comparison with linear measurements. Neuroradiology, 2018, 60, 427-436.	2.2	22
146	National Impact of the EPEC-Pediatrics Enhanced Train-the-Trainer Model for Delivering Education on Pediatric Palliative Care. Journal of Palliative Medicine, 2018, 21, 1249-1256.	1.1	22
147	Predictors of neuropsychological late effects and white matter correlates in children treated for a brain tumor without radiation therapy. Pediatric Blood and Cancer, 2019, 66, e27924.	1.5	22
148	Web-based survey of resources for treatment and long-term follow-up for children with brain tumors in developing countries. Child's Nervous System, 2011, 27, 1957-1961.	1.1	21
149	Recommendations for the treatment of children with radiotherapy in lowâ€•and middleâ€income countries (LMIC): A position paper from the Pediatric Radiation Oncology Society (PROSâ€LMIC) and Pediatric Oncology in Developing Countries (PODC) working groups of the International Society of Pediatric Oncology (SIOP). Pediatric Blood and Cancer, 2017, 64, e26903.	1.5	21
150	SIOP PODC Adapted treatment guidelines for low grade gliomas in low and middle income settings. Pediatric Blood and Cancer, 2017, 64, e26737.	1.5	21
151	DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. Clinical Epigenetics, 2019, 11, 117.	4.1	21
152	Molecular correlates of cerebellar mutism syndrome in medulloblastoma. Neuro-Oncology, 2020, 22, 290-297.	1.2	21
153	PPAR and GST polymorphisms may predict changes in intellectual functioning in medulloblastoma survivors. Journal of Neuro-Oncology, 2019, 142, 39-48.	2.9	21
154	Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature. Journal of Neuro-Oncology, 2020, 147, 721-730.	2.9	21
155	A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors.. Journal of Clinical Oncology, 2012, 30, 9519-9519.	1.6	21
156	Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive. Journal of Neuro-Oncology, 2015, 124, 247-253.	2.9	20
157	Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. Journal of Neuro-Oncology, 2016, 129, 131-138.	2.9	20
158	Comparison of Epidemiology and Outcomes in Neuro-Oncology Between the East and the West: Challenges and Opportunities. Clinical Oncology, 2019, 31, 539-548.	1.4	20
159	Mutations in the RAS/MAPK Pathway Drive Replication Repairâ€“Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. Cancer Discovery, 2021, 11, 1454-1467.	9.4	19
160	Gamma Deficits as a Neural Signature of Cognitive Impairment in Children Treated for Brain Tumors. Journal of Neuroscience, 2014, 34, 8813-8824.	3.6	18
161	Challenges of Treating Childhood Medulloblastoma in a Country With Limited Resources: 20 Years of Experience at a Single Tertiary Center in Malaysia. Journal of Global Oncology, 2017, 3, 143-156.	0.5	18
162	Re-irradiation for children with recurrent medulloblastoma in Toronto, Canada: a 20-year experience. Journal of Neuro-Oncology, 2019, 145, 107-114.	2.9	18

#	Article	IF	Citations
163	Isolated optic nerve gliomas: a multicenter historical cohort study. Journal of Neurosurgery: Pediatrics, 2017, 20, 549-555.	1.3	17
164	Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma. Journal of Pediatric Hematology/Oncology, 2018, 40, 478-482.	0.6	17
165	Bevacizumab for NF2â€associated vestibular schwannomas of childhood and adolescence. Pediatric Blood and Cancer, 2020, 67, e28228.	1.5	17
166	Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600â€“mutant relapsed refractory low-grade glioma.. Journal of Clinical Oncology, 2018, 36, 10506-10506.	1.6	17
167	Prognostic relevance of miRâ€124â€3p and its target TP53INP1 in pediatric ependymoma. Genes Chromosomes and Cancer, 2017, 56, 639-650.	2.8	16
168	Intellectual changes after radiation for children with brain tumors: which brain structures are most important?. Neuro-Oncology, 2021, 23, 487-497.	1.2	16
169	SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohortâ€”A BIOMECA Consortium Study. Neuro-Oncology, 2022, 24, 936-948.	1.2	16
170	Early changes in white matter predict intellectual outcome in children treated for posterior fossa tumors. NeuroImage: Clinical, 2018, 20, 697-704.	2.7	15
171	Impaired Recent, but Preserved Remote, Autobiographical Memory in Pediatric Brain Tumor Patients. Journal of Neuroscience, 2018, 38, 8251-8261.	3.6	15
172	Management of high-risk medulloblastoma. Neurochirurgie, 2021, 67, 61-68.	1.2	15
173	Second re-irradiation for DIPG progression, re-considering â€œold strategiesâ€•with new approaches. Child's Nervous System, 2017, 33, 849-852.	1.1	14
174	Review of management and morbidity of pediatric craniopharyngioma patients in a low-middle-income country: a 12-year experience. Child's Nervous System, 2017, 33, 941-950.	1.1	14
175	Video-Teleconferencing in Pediatric Neuro-Oncology: Ten Years of Experience. Journal of Global Oncology, 2018, 4, 1-7.	0.5	14
176	Repeat irradiation for children with supratentorial highâ€grade glioma. Pediatric Blood and Cancer, 2019, 66, e27881.	1.5	14
177	Pediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectives. JCO Global Oncology, 2020, 6, 1264-1275.	1.8	14
178	Long term toxicity of intracranial germ cell tumor treatment in adolescents and young adults. Journal of Neuro-Oncology, 2020, 149, 523-532.	2.9	14
179	Cancers from Novel Pole-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade. Cancer Research, 2020, 80, 5606-5618.	0.9	14
180	Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment. JAMA Oncology, 2021, 7, 1550.	7.1	14

#	Article	IF	Citations
181	Synchronous glioblastoma and medulloblastoma in a child with mismatch repair mutation. Child's Nervous System, 2016, 32, 553-557.	1.1	13
182	Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. Acta Neuropathologica Communications, 2018, 6, 67.	5.2	12
183	Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen. Neuro-Oncology, 2020, 22, 1873-1881.	1.2	12
184	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. The Lancet Child and Adolescent Health, 2021, 5, 800-813.	5.6	12
185	Dabrafenib in pediatric patients with BRAF V600â€“positive high-grade glioma (HGG).. Journal of Clinical Oncology, 2018, 36, 10505-10505.	1.6	12
186	Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource-Limited Country. JCO Global Oncology, 2021, 7, 1442-1453.	1.8	12
187	Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials. Neuro-Oncology, 2022, 24, 1950-1961.	1.2	12
188	Balancing grief and survival: Experiences of children with brain tumors and their parents. Journal of Psychosocial Oncology, 2016, 34, 376-399.	1.2	11
189	Critical review of the management of primary central nervous nongerminomatous germ cell tumors. Pediatric Blood and Cancer, 2019, 66, e27658.	1.5	11
190	Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. Cancer Medicine, 2020, 9, 447-459.	2.8	11
191	Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children. Journal of Clinical Oncology, 2021, 39, 3813-3821.	1.6	11
192	Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results.. Journal of Clinical Oncology, 2020, 38, 10506-10506.	1.6	11
193	Embryonal tumours of the central nervous system. European Journal of Cancer, 2002, 38, 1112-1120.	2.8	10
194	Facial emotion recognition in children treated for posterior fossa tumours and typically developing children: A divergence of predictors. NeuroImage: Clinical, 2019, 23, 101886.	2.7	10
195	Trametinib Toxicities in Patients With Low-grade Gliomas and Diabetes Insipidus: Related Findings?. Journal of Pediatric Hematology/Oncology, 2020, 42, e248-e250.	0.6	10
196	Causes of death in pediatric neuro-oncology: the sickkids experience from 2000 to 2017. Journal of Neuro-Oncology, 2020, 149, 181-189.	2.9	10
197	Position paper: Challenges and specific strategies for constitutional mismatch repair deficiency syndrome in lowâ€resource settings. Pediatric Blood and Cancer, 2020, 67, e28309.	1.5	10
198	Pediatric cancer care in Africa: SIOP Global MappingÂProgramÂreport on economic and population indicators. Pediatric Blood and Cancer, 2021, 68, e29345.	1.5	10

#	Article	IF	Citations
199	The clinical significance of equivocal findings on spinal MRI in children with medulloblastoma. Pediatric Blood and Cancer, 2017, 64, e26472.	1.5	9
200	Diffuse intrinsic pontine glioma ventricular peritoneal shunt metastasis: a case report and literature review. Child's Nervous System, 2019, 35, 861-864.	1.1	9
201	Disrupted network connectivity in pediatric brain tumor survivors is a signature of injury. Journal of Comparative Neurology, 2019, 527, 2896-2909.	1.6	9
202	Bevacizumab for pediatric radiation necrosis. Neuro-Oncology Practice, 2020, 7, 409-414.	1.6	9
203	Embryonal tumors with multi-layered rosettes: a disease of dysregulated miRNAs. Journal of Neuro-Oncology, 2020, 150, 63-73.	2.9	9
204	Intracranial ependymomas in children: A critical review of prognostic factors and a plea for cooperation. Medical and Pediatric Oncology, 1998, 30, 319-329.	1.0	9
205	Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. Neuro-Oncology, 2022, 24, 821-833.	1.2	9
206	Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1. Neuro-Oncology, 2022, 24, 1377-1386.	1.2	9
207	Dabrafenib + trametinib (dab + tram) in relapsed/refractory (r/r) BRAF V600â€“mutant pediatric high-grade glioma (pHGG): Primary analysis of a phase II trial.. Journal of Clinical Oncology, 2022, 40, 2009-2009.	1.6	9
208	Second rhabdoid tumor 8 years after treatment of atypical teratoid/rhabdoid tumor in a child with germline SMARCB1 mutation. Pediatric Blood and Cancer, 2019, 66, e27546.	1.5	8
209	BRAF V600E mutant oligodendrogliomaâ€like tumors with chromosomal instability in adolescents and young adults. Brain Pathology, 2020, 30, 515-523.	4.1	8
210	Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC). Journal of Neuro-Oncology, 2020, 149, 45-54.	2.9	8
211	SIOP PODCâ€“adapted treatment guidelines for craniopharyngioma in lowâ€and middleâ€income settings. Pediatric Blood and Cancer, 2023, 70, e28493.	1.5	8
212	The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). Journal of Neuro-Oncology, 2020, 147, 731-736.	2.9	8
213	Hearing loss and intellectual outcome in children treated for embryonal brain tumors: Implications for young children treated with radiation sparing approaches. Cancer Medicine, 2021, 10, 7111-7125.	2.8	8
214	Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study. JCO Precision Oncology, 2022, 6, e2100286.	3.0	8
215	Reducing cisplatin ototoxicity in children: some hope and many questions. Lancet Oncology, The, 2017, 18, 6-7.	10.7	7
216	Redefining Ventricular Target Volume in Germinoma: Is Inclusion of Temporal Horns Necessary?. International Journal of Radiation Oncology Biology Physics, 2019, 104, 852-858.	0.8	7

#	Article	IF	Citations
217	Ongoing issues with the management of children with Constitutional Mismatch Repair Deficiency syndrome. European Journal of Medical Genetics, 2019, 62, 103706.	1.3	7
218	Effective and safe tumor inhibition using vinblastine in medulloblastoma. Pediatric Blood and Cancer, 2019, 66, e27694.	1.5	7
219	WNT-activated embryonal tumors of the pineal region: ectopic medulloblastomas or a novel pineoblastoma subgroup?. Acta Neuropathologica, 2020, 140, 595-597.	7.7	7
220	ACNS1221: A phase II study for the treatment of non metastatic desmoplastic medulloblastoma in children less than 4 years of ageâ€"A report from the Children Oncology Group.. Journal of Clinical Oncology, 2017, 35, 10505-10505.	1.6	7
221	Common Brain Tumours in Children. Paediatric Drugs, 2000, 2, 57-66.	3.1	6
222	Old chemotherapy makes a comeback: dual alkylator therapy for pediatric high-grade glioma. Neuro-Oncology, 2016, 18, 1333-1334.	1.2	6
223	Underlying undiagnosed inherited marrow failure syndromes among children with cancer. Pediatric Blood and Cancer, 2017, 64, 302-305.	1.5	6
224	Pediatric embryonal brain tumors in the molecular era. Expert Review of Molecular Diagnostics, 2020, 20, 293-303.	3.1	6
225	Eye Movements and White Matter are Associated with Emotional Control in Children Treated for Brain Tumors. Journal of the International Neuropsychological Society, 2020, 26, 978-992.	1.8	6
226	Family environment as a predictor and moderator of cognitive and psychosocial outcomes in children treated for posterior fossa tumors. Child Neuropsychology, 2021, 27, 641-660.	1.3	6
227	Challenges in the Management of Childhood Intracranial Germ Cell Tumors in Middle-Income Countries. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, e913-e923.	0.6	6
228	An Audiovisual 3D-Immersive Stimulation Program in Hemianopia Using a Connected Device. American Journal of Case Reports, 2021, 22, e931079.	0.8	6
229	Upfront Adjuvant Immunotherapy of Replication Repairâ€"Deficient Pediatric Glioblastoma With Chemoradiation-Sparing Approach. JCO Precision Oncology, 2021, 5, 1426-1431.	3.0	6
230	Paediatric atypical choroid plexus papilloma: is adjuvant therapy necessary?. Journal of Neuro-Oncology, 2021, 155, 63-70.	2.9	6
231	Incidence of childhood cancer in Canada during the COVID-19 pandemic. Cmaj, 2021, 193, E1798-E1806.	2.0	6
232	Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national realâ€world case series. Pediatric Blood and Cancer, 2022, 69, e29633.	1.5	6
233	Pediatric Pineoblastoma: A pooled outcome study of North American and Australian therapeutic data. Neuro-Oncology Advances, 0, , .	0.7	6
234	Radiomic Features Based on MRI Predict Progression-Free Survival in Pediatric Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma. Canadian Association of Radiologists Journal, 2023, 74, 119-126.	2.0	6

#	Article	IF	Citations
235	Implementing the WHO Global Initiative for Childhood Cancer in Morocco: Survival study for the six indexed childhood cancers. Pediatric Blood and Cancer, 2022, 69, .	1.5	6
236	Chemotherapy in Childhood Brain Tumors. Current Pediatrics Reports, 2014, 2, 38-49.	4.0	5
237	End-of-life care of children with diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2018, 138, 147-153.	2.9	5
238	The silent victims of the US embargo against Iran. Lancet Oncology, The, 2018, 19, e580.	10.7	5
239	Highâ€dose chemotherapy with autologous stem cell transplantation in infants and young children with ependymoma: A 10â€year experience with the Head Start II protocol. Pediatric Transplantation, 2019, 23, e13421.	1.0	5
240	Feasibility of highâ€dose chemotherapy protocols to treat infants with malignant central nervous system tumors: Experience from a middleâ€income country. Pediatric Blood and Cancer, 2019, 66, e27464.	1.5	5
241	Treatment response of CNS highâ€grade neuroepithelial tumors with MN1 alteration. Pediatric Blood and Cancer, 2020, 67, e28627.	1.5	5
242	Pilot study of nivolumab in pediatric patients with hypermutant cancers.. Journal of Clinical Oncology, 2021, 39, 10011-10011.	1.6	5
243	Case Report: Visual Rehabilitation in Hemianopia Patients. Home-Based Visual Rehabilitation in Patients With Hemianopia Consecutive to Brain Tumor Treatment: Feasibility and Potential Effectiveness. Frontiers in Neurology, 2021, 12, 680211.	2.4	5
244	COVID-19 in pediatric cancer: Where are the brain tumors?. Neuro-Oncology, 2021, 23, 1977-1979.	1.2	5
245	Pediatric cancer care in Africa: SIOP Global Mapping process. Pediatric Blood and Cancer, 2021, 68, e29315.	1.5	5
246	Re-evaluating surgery and re-irradiation for locally recurrent pediatric ependymoma â€“ a multi-institutional study. Neuro-Oncology Advances, 2021, 3, vdab158.	0.7	5
247	The influence of central review on outcome in malignant gliomas of the spinal cord: the CCG-945 experience. Journal of Neurosurgery: Pediatrics, 2016, 17, 453-459.	1.3	4
248	Societal preferences in the treatment of pediatric medulloblastoma: Balancing risk of death and quality of life. Pediatric Blood and Cancer, 2017, 64, e26340.	1.5	4
249	Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218. Pediatric Blood and Cancer, 2019, 66, e27540.	1.5	4
250	Indolent course of brainstem tumors with K27Mâ€H3.3 mutation. Pediatric Blood and Cancer, 2020, 67, e28102.	1.5	4
251	The threat of the COVID-19 pandemic on reversing global life-saving gains in the survival of childhood cancer: a call for collaborative action from SIOP, IPSO, PROS, WCC, CCI, St Jude Global, UICC and WHPCA. Ecancermedicalscience, 2021, 15, 1187.	1.1	4
252	Bridging the Gap: Exploring the Impact of Hospital Isolation on Peer Relationships Among Children and Adolescents with a Malignant Brain Tumor. Child and Adolescent Social Work Journal, 2021, , 1-15.	1.4	4

#	Article	IF	Citations
253	Building the ecosystem for pediatric neuroâ€oncology care in Pakistan: Results of a 7â€year long twinning program between Canada and Pakistan. Pediatric Blood and Cancer, 2022, 69, e29726.	1.5	4
254	Optic Pathway Glioma in Children with Neurofibromatosis Type 1: A Multidisciplinary Entity, Posing Dilemmas in Diagnosis and Management Multidisciplinary Management of Optic Pathway Glioma in Children with Neurofibromatosis Type 1. Frontiers in Surgery, 2022, 9, 886697.	1.4	4
255	Embryonal tumors in Canadian children less than 36 months of age: results from the Canadian Pediatric Brain Tumor Consortium (CPBTC). Journal of Neuro-Oncology, 2017, 133, 581-587.	2.9	3
256	Reirradiation for recurrent craniopharyngioma. Advances in Radiation Oncology, 2020, 5, 1305-1310.	1.2	3
257	Brainstem gliomas â€¦ the devil is in the details. Neuro-Oncology, 2021, 23, 869-871.	1.2	3
258	Diffuse intrinsic pontine glioma: a clinic in Mexico, social media, and unpublishable data. Lancet Oncology, The, 2021, 22, 595-596.	10.7	3
259	Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors. Pediatric Blood and Cancer, 2022, 69, e29365.	1.5	3
260	Ventricular size determination and management of ventriculomegaly and hydrocephalus in patients with diffuse intrinsic pontine glioma: an institutional experience. Journal of Neurosurgery, 2021, 135, 1139-1145.	1.6	3
261	Relationship of BRAF V600E and associated secondary mutations on survival rate and response to conventional therapies in childhood low-grade glioma.. Journal of Clinical Oncology, 2016, 34, 10509-10509.	1.6	3
262	NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY. Neuro-Oncology, 2020, 22, iii419-iii419.	1.2	3
263	The impact of the COVIDâ€19 pandemic in pediatric oncology units: A lesson of resilience and hope. Cancer, 2022, 128, 1363-1364.	4.1	3
264	Clinical and molecular characteristics of pediatric low-grade glioma complicated with ventriculo-peritoneal shunt related ascites. Journal of Neuro-Oncology, 2022, 157, 147-156.	2.9	3
265	Impact of home-based cognitive or academic intervention on working memory and mathematics outcomes in pediatric brain tumor survivors: the Keys to Succeed pilot randomized controlled clinical trial. Child Neuropsychology, 2022, 28, 1116-1140.	1.3	3
266	Reply to J.C. Lindsey et al. Journal of Clinical Oncology, 2011, 29, e347-e347.	1.6	2
267	Profound Answers to Simple Questions. Journal of Clinical Oncology, 2015, 33, 1294-1296.	1.6	2
268	Proton beam therapy for medulloblastoma. Lancet Oncology, The, 2016, 17, e173-e174.	10.7	2
269	MBCL-08. MOLECULAR CHARACTERIZATION OF NODULAR DESMOPLASTIC MEDULLOBLASTOMAS IN YOUNG CHILDREN TREATED ON ACNS1221. A REPORT FROM THE CHILDREN ONCOLOGY GROUP. Neuro-Oncology, 2018, 20, i118-i119.	1.2	2
270	Neuropsychological impact of trametinib in pediatric lowâ€grade glioma: A case series. Pediatric Blood and Cancer, 2020, 67, e28690.	1.5	2

#	Article	IF	Citations
271	Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E lowâ€grade glioma. Pediatric Blood and Cancer, 2021, 68, e28561.	1.5	2
272	Reâ€irradiation with concurrent BRAF and MEK inhibitor therapy. Pediatric Blood and Cancer, 2021, 68, e28838.	1.5	2
273	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma. Neuro-Oncology Advances, 2021, 3, vdab002.	0.7	2
274	Treatment abandonment and refusal among children with central nervous system tumors in Jordan. Pediatric Blood and Cancer, 2021, 68, e29054.	1.5	2
275	Posterior fossa syndromeâ€"time to unmute the silence on cerebellar mutism. Neuro-Oncology, 2021, 23, 1427-1428.	1.2	2
276	Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma. Pediatric Blood and Cancer, 2022, 69, e29316.	1.5	2
277	SYST-04. TRAM-01: A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. Neuro-Oncology Advances, 2021, 3, iv9-iv9.	0.7	2
278	Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study.. Journal of Clinical Oncology, 2013, 31, 10029-10029.	1.6	2
279	MBCL-24. CAN YOUNG CHILDREN WITH RELAPSED MEDULLOBLASTOMA BE SALVAGED AFTER INITIAL IRRADIATION-SPARING APPROACHES?. Neuro-Oncology, 2020, 22, iii393-iii393.	1.2	2
280	Successful management of symptomatic hydrocephalus using a temporary external ventricular drain with or without endoscopic third ventriculostomy in pediatric patients with germinoma. Journal of Neurosurgery, 2021, , 1-6.	1.6	2
281	GCT-22. OUTCOMES OF CHILDREN WITH LOCALIZED AND METASTATIC GERMINOMA TREATED WITH CHEMOTHERAPY FOLLOWED BY RADIATION THERAPY WITHOUT PRIMARY TUMOR BOOST. Neuro-Oncology, 2022, 24, i59-i59.	1.2	2
282	A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway.. Journal of Clinical Oncology, 2022, 40, 2042-2042.	1.6	2
283	Comment to the paper â€œSurgical outcome of patients considered to have â€œinoperableâ€•tumors by specialized pediatric neurooncological multi-disciplinary teamsâ€• Child's Nervous System, 2010, 26, 1227-1228.	1.1	1
284	HG-37SECOND RE-IRRADIATION FOR DIPG PROGRESSION, RE-CONSIDERING â€œOLD STRATEGIESâ€•WITH NEW APPROACHES. Neuro-Oncology, 2016, 18, iii55.4-iii56.	1.2	1
285	LG-19IMMUNOHISTOCHEMISTRY IS HIGHLY SENSITIVE AND SPECIFIC FOR THE DETECTION OF BRAF V600E STATUS IN PEDIATRIC LOW-GRADE GLIOMA. Neuro-Oncology, 2016, 18, iii82.3-iii82.	1.2	1
286	Pain Management and Use of Opioids in Pediatric Oncology in India: A Qualitative Approach. Journal of Global Oncology, 2017, 3, 331-337.	0.5	1
287	RTHP-34. CRANIOSPINAL IRRADIATION (CSI) AS PART OF RE-IRRADIATION (RT2) FOR CHILDREN WITH RECURRENT INTRACRANIAL EPENDYMOMA. Neuro-Oncology, 2018, 20, vi232-vi232.	1.2	1
288	How do parents and providers trade-off between disability and survival? Preferences in the treatment of pediatric medulloblastoma. Patient Preference and Adherence, 2018, Volume 12, 2103-2110.	1.8	1

#	Article	IF	Citations
289	Selumetinib in paediatric low-grade glioma: a new era?. Lancet Oncology, The, 2019, 20, 900-901.	10.7	1
290	Reply to S.A. Milgrom et al. Journal of Clinical Oncology, 2020, 38, 2212-2213.	1.6	1
291	Neuro-oncology in adolescents and young adultsâ€"an unmet need. Neuro-Oncology, 2020, 22, 752-753.	1.2	1
292	Early signs of metabolic syndrome in pediatric central nervous system tumor survivors after high-dose chemotherapy and autologous stem-cell transplantation and radiation. Child's Nervous System, 2021, 37, 1087-1094.	1.1	1
293	EPEN-04. SIOP EPENDYMOMA I: FINAL RESULTS, LONG TERM FOLLOW-UP AND MOLECULAR ANALYSIS OF THE TRIAL COHORT: A BIOMECA CONSORTIUM STUDY. Neuro-Oncology, 2021, 23, i14-i14.	1.2	1
294	Establishing a pediatric radiation oncology department in a lowâ€•and middleâ€•income country: Major challenge in implementing the Global Initiative for Childhood Cancer. Pediatric Blood and Cancer, 2021, 68, e29233.	1.5	1
295	Childhood head trauma and the risk of childhood brain tumours: A caseâ€•control study in Ontario, Canada. International Journal of Cancer, 2022, 150, 795-801.	5.1	1
296	IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY. Neuro-Oncology, 2020, 22, iii363-iii363.	1.2	1
297	MBRS-54. POOR SURVIVAL IN REPLICATION REPAIR DEFICIENT HYPERMUTANT MEDULLOBLASTOMA AND CNS EMBRYONAL TUMORS: A REPORT FROM THE INTERNATIONAL RRD CONSORTIUM. Neuro-Oncology, 2020, 22, iii407-iii407.	1.2	1
298	Microvessel density predicts behavior in pediatric optic pathway/hypothalamic gliomas. Journal of Clinical Oncology, 2004, 22, 1556-1556.	1.6	1
299	Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study.. Journal of Clinical Oncology, 2015, 33, 2019-2019.	1.6	1
300	Re-irradiation for relapsed paediatric ependymoma.. Journal of Clinical Oncology, 2016, 34, 10565-10565.	1.6	1
301	LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG). Neuro-Oncology, 2020, 22, iii375-iii375.	1.2	1
302	LGG-25. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. Neuro-Oncology, 2020, 22, iii371-iii371.	1.2	1
303	CTNI-06. TRAM-01: A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. Neuro-Oncology, 2021, 23, vi59-vi60.	1.2	1
304	IMMU-13. Dual CTLA4/ PD-1 blockade improves survival for replication-repair deficient high-grade gliomas failing single agent PD-1 inhibition: An IRRDC study. Neuro-Oncology, 2022, 24, i84-i84.	1.2	1
305	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107.	1.2	1
306	How do we approach the management of medulloblastoma in young children?. Pediatric Blood and Cancer, 0, , .	1.5	1

#	Article	IF	Citations
307	Infantile suprasellar tumor diagnosed as a pineoblastoma RB1 subgroup and treatment challenges: A pediatric SNO Molecular Tumor Board. Neuro-Oncology Advances, 2022, 4, .	0.7	1
308	Structural connectivity and intelligence in brain-injured children. Neuropsychologia, 2022, 173, 108285.	1.6	1
309	The impact of initial radiation in infants and the re-irradiation of recurrent disease on the survival of ependymoma patients at The Hospital for Sick Children, Toronto. Canadian Journal of Neurological Sciences, 2014, 41, S6-S6.	0.5	0
310	Outcomes of children with central nervous system (CNS) germinoma treated with carboplatin-based chemotherapy followed by reduced radiation. Canadian Journal of Neurological Sciences, 2014, 41, S6-S6.	0.5	0
311	DETAILED MOLECULAR CHARACTERISATION OF DIFFUSE INTRINSIC PONTINE GLIOMAS IDENTIFIES THREE MOLECULAR SUBGROUPS AND A NOVEL CANCER DRIVER, ACVR1. Neuro-Oncology, 2014, 16, iii26-iii27.	1.2	0
312	AT-07 * SUCCESSFUL TREATMENT OF ATRT PATIENTS WITHOUT ADJUVANT RADIATION: A MULTI INSTITUTIONAL CANADIAN EXPERIENCE. Neuro-Oncology, 2015, 17, iii2-iii2.	1.2	0
313	Reply to L. Wiener et al. Journal of Clinical Oncology, 2015, 33, 3975-3975.	1.6	0
314	MB-35 * VERY ENCOURAGING LONG-TERM SURVIVAL AND NEUROCOGNITIVE OUTCOME OF YOUNG CHILDREN TREATED FOR MEDULLOBLASTOMA WITH SEQUENTIAL HIGH DOSE CHEMOTHERAPY. Neuro-Oncology, 2015, 17, iii28-iii28.	1.2	0
315	LG-66CLINICAL AND TREATMENT FACTORS DETERMINING LONG-TERM OUTCOMES FOR ADULT SURVIVORS OF CHILDHOOD LOW-GRADE GLIOMA: A POPULATION-BASED STUDY. Neuro-Oncology, 2016, 18, iii94.1-iii94.	1.2	0
316	RA-10SUBTLE FINDINGS ON SPINAL MRIs IN CHILDREN NEWLY DIAGNOSED WITH MEDULLOBLASTOMA. Neuro-Oncology, 2016, 18, iii166.5-iii167.	1.2	0
317	CMS-03RISK FACTORS FOR LONG TERM SPEECH DEFICITS IN CHILDREN WITH CEREBELLAR MUTISM SYNDROME. Neuro-Oncology, 2016, 18, iii16.3-iii16.	1.2	0
318	MB-96IMPAIRED NEURAL FUNCTION DURING VISUAL-MOTOR PERFORMANCE IN CHILDREN TREATED FOR BRAIN TUMOURS. Neuro-Oncology, 2016, 18, iii119.1-iii119.	1.2	0
319	QOS-06REPAIRING THE BRAIN WITH PHYSICAL EXERCISE: AN EXERCISE TRIAL IN PEDIATRIC BRAIN TUMOR SURVIVORS. INSIGHTS FROM CORTICAL THICKNESS ANALYSIS AND DEFORMATION BASED MORPHOMETRY. Neuro-Oncology, 2016, 18, iii146.2-iii146.	1.2	0
320	AT-21INTEGRATED (EPI)GENOMIC ANALYSES IDENTIFY SUB-GROUP SPECIFIC THERAPEUTIC TARGETS IN CNS RHABDOID TUMORS. Neuro-Oncology, 2016, 18, iii6.1-iii6.	1.2	0
321	CMS-09BEHAVIOR AND TEMPERAMENT IN CHILDREN TREATED FOR PEDIATRIC MEDULLOBLASTOMA WITH POSTOPERATIVE CEREBELLAR MUTISM SYNDROME. Neuro-Oncology, 2016, 18, iii17.4-iii17.	1.2	0
322	La SociÃ©tÃ© internationale dâ€™oncologie pÃ©diatriqueÂ: passÃ©, prÃ©sent et perspectives dâ€™avenir. Revue D'Oncologie HÃ©matologie PÃ©diatrique, 2017, 5, 5-9.	0.1	0
323	Why itâ€™s time for a change in the management of adolescent and adult medulloblastoma. Expert Review of Quality of Life in Cancer Care, 2017, 2, 207-213.	0.6	0
324	QOL-09. EMOTION RECOGNITION IN PEDIATRIC BRAIN TUMOR PATIENTS: VIEWING PATTERNS AND WHITE MATTER STRUCTURE. Neuro-Oncology, 2018, 20, i159-i159.	1.2	0

#	Article	IF	Citations
325	GERM-23. INTRACRANIAL GROWING TERATOMA SYNDROME (IGTS): AN INTERNATIONAL RETROSPECTIVE STUDY. Neuro-Oncology, 2018, 20, i88-i88.	1.2	0
326	Reply to D.T.W. Jones et al. Journal of Clinical Oncology, 2018, 36, 97-97.	1.6	0
327	LGG-10. EPIGENETIC/GENETIC/MORPHOLOGIC ANALYSES REVEAL CLINICAL/PROGNOSTIC INSIGHT OF PEDIATRIC LOW GRADE GLIOMAS. Neuro-Oncology, 2018, 20, i106-i106.	1.2	0
328	ATRT-40. IMPACT OF MOLECULAR SUBTYPES ON TREATMENT OUTCOMES IN RHABDOID TUMORS - A REPORT FROM THE RARE TUMOR CONSORTIUM. Neuro-Oncology, 2018, 20, i36-i36.	1.2	0
329	EPEN-31. SUBGROUP SPECIFIC LONG-TERM SURVIVAL AND NEUROCOGNITIVE OUTCOMES IN POSTERIOR FOSSA EPENDYMOMA (PFE). Neuro-Oncology, 2018, 20, i79-i79.	1.2	0
330	HGG-17. TUMOR MUTATIONAL BURDEN ANALYSIS OF PEDIATRIC TUMORS PROVIDES A DIAGNOSTIC TOOL FOR GERMLINE REPLICATION REPAIR DEFICIENCY AND PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION. Neuro-Oncology, 2018, 20, i92-i92.	1.2	0
331	QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 2018, 20, i168-i168.	1.2	0
332	EAPH-06. HYPERMUTANT PEDIATRIC HIGH GRADE GLIOMAS ARE DRIVEN BY RAS/MAPK MUTATIONS AND RESPOND TO MEK INHIBITION. Neuro-Oncology, 2018, 20, i66-i66.	1.2	0
333	EMBR-14. RECLASSIFICATION OF CENTRAL NERVOUS SYSTEM PRIMITIVE NEUROECTODERMAL TUMOR (CNS-PNET) INTO ENTITIES REFLECTS OUTCOME: RESULTS FROM THE PROSPECTIVE SJYC07 AND SJMB03 TRIALS. Neuro-Oncology, 2018, 20, i71-i72.	1.2	0
334	TBIO-30. MOLECULAR LANDSCAPE AND CLINICAL CORRELATIONS OF CNS SARCOMAS. Neuro-Oncology, 2018, 20, i186-i186.	1.2	0
335	CRAN-29. CONSERVATIVE SURGERY FOLLOWED BY PROTON THERAPY FOR CRANIOPHARYNGIOMA IN CHILDREN: A PHASE II STUDY TO EXAMINE THE FEASIBILITY OF DOSE ESCALATION. Neuro-Oncology, 2018, 20, i42-i43.	1.2	0
336	DIPG-23. BRAINSTEM RADIATION EXPOSURE CONFERS SUBSTANTIAL RISK OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) IN MEDULLOBLASTOMA SURVIVORS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2018, 20, i53-i53.	1.2	0
337	EMBR-13. FAVORABLE OUTCOMES IN CHILDREN WITH PINEOBLASTOMA TREATED WITH RISK-ADAPTED CRANIOSPINAL IRRADIATION AND CHEMOTHERAPY: RESULTS AND MOLECULAR ANALYSIS FROM THE SJYC07 AND SJMB03 TRIALS. Neuro-Oncology, 2018, 20, i71-i71.	1.2	0
338	LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. Neuro-Oncology, 2018, 20, i117-i117.	1.2	0
339	EMBR-17. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOR CONSORTIUM. Neuro-Oncology, 2018, 20, i72-i73.	1.2	0
340	ATRT-36. META-ANALYSIS OF TREATMENT MODALITIES IN METASTATIC ATYPICAL TERATOID/RHABDOID TUMORS IN CHILDREN. Neuro-Oncology, 2018, 20, i35-i35.	1.2	0
341	DEV-17. WHO ARE THE HIGH RISK MEDULLOBLASTOMA SUBGROUPS IN JORDAN?. Neuro-Oncology, 2018, 20, i48-i48.	1.2	0
342	LGG-07. CLINICAL FEATURES OF NON-CANONICAL MOLECULAR DRIVERS IN PLGG; AN UPDATE FORM THE INTERNATIONAL PLGG TASKFORCE. Neuro-Oncology, 2019, 21, ii100-ii100.	1.2	0

#	Article	IF	Citations
343	IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL REPLICATION REPAIR DEFICIENCY CONSORTIUM. Neuro-Oncology, 2019, 21, ii96-ii97.	1.2	0
344	LGG-01. BRAF V600E MUTANT OLIGODENDROGLIOMA-LIKE TUMORS WITH CHROMOSOMAL INSTABILITY IN ADOLESCENT AND YOUNG ADULT. Neuro-Oncology, 2019, 21, ii98-ii98.	1.2	0
345	PDCT-08. SUPERIOR OUTCOME FOR BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. Neuro-Oncology, 2019, 21, vi184-vi185.	1.2	0
346	PDTM-24. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOUR CONSORTIUM. Neuro-Oncology, 2019, 21, vi192-vi192.	1.2	0
347	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. Neuro-Oncology, 2019, 21, ii102-ii102.	1.2	0
348	TMOD-10. REPLICATION REPAIR DEFICIENT MOUSE MODELS PROVIDE INSIGHT ON HYPERMUTANT BRAIN TUMOURS AND COMBINATIONAL IMMUNOTHERAPY. Neuro-Oncology, 2019, 21, ii123-ii123.	1.2	0
349	In Reply to Byun etÂal. International Journal of Radiation Oncology Biology Physics, 2020, 106, 219-220.	0.8	0
350	ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. Neuro-Oncology, 2020, 22, iii327-iii328.	1.2	0
351	Carboplatin hypersensitivity reaction in pediatric low grade glioma (LGG) patients: A national experience. On behalf of the Canadian Pediatric Brain Tumor Consortium. Journal of Clinical Oncology, 2006, 24, 9053-9053.	1.6	0
352	Telomere maintenance predicts progression and survival in pediatric intracranial ependymoma. Journal of Clinical Oncology, 2006, 24, 10020-10020.	1.6	0
353	Attitudes of Researchers to the Return of Incidental and Targeted Genomic Findings Obtained in a Research Setting to Participants. Blood, 2012, 120, 2069-2069.	1.4	0
354	Pulmonary function after treatment for embryonal brain tumors on SJMB03 that included craniospinal irradiation.. Journal of Clinical Oncology, 2013, 31, 10021-10021.	1.6	0
355	Attitudes to the return of incidental and targeted genomic findings obtained in a high-risk pediatric cancer versus an inherited genetic condition research setting.. Journal of Clinical Oncology, 2013, 31, 10066-10066.	1.6	0
356	Incidence of second primary cancers with pediatric high grade glioma: Single institution experience.. Journal of Clinical Oncology, 2015, 33, e21023-e21023.	1.6	0
357	Imaging of metastatic medulloblastoma in the molecular era.. Journal of Clinical Oncology, 2016, 34, e22003-e22003.	1.6	0
358	Molecular alterations to predict survival and response to chemotherapy of pediatric low-grade glioma.. Journal of Clinical Oncology, 2017, 35, 10503-10503.	1.6	0
359	Neurocognitive outcome in children with sensorineural hearing loss after treatment of malignant embryonal brain tumors.. Journal of Clinical Oncology, 2017, 35, 2029-2029.	1.6	0
360	Who are the high risk medulloblastoma subgroups in Jordan?. Journal of Clinical Oncology, 2018, 36, e22506-e22506.	1.6	0

#	Article	IF	Citations
361	Genomic landscape of pineoblastoma.. Journal of Clinical Oncology, 2018, 36, 2028-2028.	1.6	0
362	The role of tumor markers for relapse detection in central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pool analysis of cooperative group clinical trials.. Journal of Clinical Oncology, 2020, 38, 2503-2503.	1.6	0
363	IMG-03. RESPONSE ASSESSMENT IN PEDIATRIC LOW-GRADE GLIOMA: RECOMMENDATIONS FROM THE RESPONSE ASSESSMENT IN PEDIATRIC NEURO-ONCOLOGY (RAPNO) WORKING GROUP. Neuro-Oncology, 2020, 22, iii355-iii355.	1.2	0
364	DIPG-20. DETERMINATION AND MANAGEMENT OF HYDROCEPHALUS IN PATIENTS WITH DIPG, AN INSTITUTIONAL EXPERIENCE. Neuro-Oncology, 2020, 22, iii291-iii291.	1.2	0
365	QOL-40. THE IMPACT OF TASK COMPLEXITY ON INFORMATION PROCESSING SPEED AND NEURAL COMMUNICATION IN PAEDIATRIC BRAIN TUMOUR SURVIVORS. Neuro-Oncology, 2020, 22, iii438-iii438.	1.2	0
366	DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2020, 22, iii301-iii302.	1.2	0
367	DIPG-55. PATTERNS OF CEREBROSPINAL FLUID DIVERSION AND SURVIVAL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2020, 22, iii297-iii298.	1.2	0
368	MODL-25. REPLICATION REPAIR DEFICIENT MOUSE MODELS PROVIDE INSIGHT ON HYPERMUTANT BRAIN TUMOURS, MECHANISMS OF IMMUNE EVASION, AND COMBINATORIAL IMMUNOTHERAPY. Neuro-Oncology, 2020, 22, iii416-iii416.	1.2	0
369	MBCL-26. FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY. Neuro-Oncology, 2020, 22, iii394-iii394.	1.2	0
370	MBRS-20. CSF-DERIVED CIRCULATING TUMOR DNA AS A BIOMARKER FOR DISEASE PROGRESSION AND TUMOR EVOLUTION IN MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii401-iii402.	1.2	0
371	DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. Neuro-Oncology, 2020, 22, iii295-iii296.	1.2	0
372	RARE-55. CHALLENGES AND SPECIFIC STRATEGIES FOR CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME IN LOW RESOURCE SETTINGS. ON BEHALF OF THE INTERNATIONAL RRD CONSORTIUM IN LOW RESOURCE SETTINGS PANEL. Neuro-Oncology, 2020, 22, iii454-iii454.	1.2	0
373	LGG-19. SPINAL LOW-GRADE GLIOMAS IN CANADIAN CHILDREN: A MULTI-CENTRE RETROSPECTIVE REVIEW. Neuro-Oncology, 2020, 22, iii369-iii370.	1.2	0
374	ETMR-21. META-ANALYSIS OF PINEAL REGION TUMOURS DEMONSTRATES MOLECULAR SUBGROUPS WITH DISTINCT CLINICO-PATHOLOGICAL FEATURES: A CONSENSUS STUDY. Neuro-Oncology, 2020, 22, iii327-iii327.	1.2	0
375	RARE-02.RE-IRRADIATION FOR RECURRENT CRANIOPHARYNGIOMA. Neuro-Oncology, 2020, 22, iii442-iii442.	1.2	0
376	QOL-01. LONGITUDINAL COMPARISON OF NEUROCOGNITIVE TRAJECTORIES IN PEDIATRIC MEDULLOBLASTOMA PATIENTS TREATED WITH PROTON VERSUS PHOTON RADIOTHERAPY. Neuro-Oncology, 2020, 22, iii431-iii431.	1.2	0
377	LINC-10. SIOP PODC ADAPTED TREATMENT GUIDELINES FOR CRANIOPHARYNGIOMA IN LOW- AND MIDDLE-INCOME SETTINGS. Neuro-Oncology, 2020, 22, iii379-iii380.	1.2	0
378	HGG-20. DIAGNOSTIC AND BIOLOGICAL ROLE OF METHYLATION PATTERNS IN REPLICATION REPAIR DEFICIENT HIGH GRADE GLIOMAS. Neuro-Oncology, 2020, 22, iii347-iii348.	1.2	0

#	Article	IF	Citations
379	ETMR-06. DISSECTING THE MOLECULAR AND DEVELOPMENTAL BASIS OF PINEOBLASTOMA THROUGH GENOMICS. Neuro-Oncology, 2020, 22, iii323-iii324.	1.2	0
380	RONC-03. NEUROCOGNITIVE CHANGES AFTER RADIATION FOR PEDIATRIC BRAIN TUMOURS: WHICH BRAIN SUBSTRUCTURES ARE MOST IMPORTANT?. Neuro-Oncology, 2020, 22, iii456-iii456.	1.2	0
381	COVD-04. CHARACTERISTICS OF SARS-COV-2 IN 64 CHILDREN WITH CNS TUMORS: A REPORT FROM THE SIOP/ST. JUDE CHILDRENâ€™S RESEARCH HOSPITAL (SJCRH) GLOBAL COVID-19 CHILDHOOD CANCER REGISTRY. Neuro-Oncology, 2020, 22, iii283-iii283.	1.2	0
382	PATH-14. GENETIC SUSCEPTIBILITY AND OUTCOMES OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT IDH-MUTANT ASTROCYTOMAS. Neuro-Oncology, 2020, 22, iii427-iii427.	1.2	0
383	GCT-75. ISOLATED PITUITARY STALK THICKENING. Neuro-Oncology, 2020, 22, iii343-iii343.	1.2	0
384	LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. Neuro-Oncology, 2020, 22, iii377-iii377.	1.2	0
385	INNV-43. MORE THAN WHAT MEETS THE EYE: ETMR AN UNDER RECOGNISED ATYPICAL BRAINSTEM PRIMARY. A RARE BRAIN TUMOR CONSORTIUM (RBTC) STUDY. Neuro-Oncology, 2021, 23, vi114-vi115.	1.2	0
386	Clinical and economic impact of molecular testing for BRAF fusion in pediatric low-grade Glioma. BMC Pediatrics, 2022, 22, 13.	1.7	0
387	Infant brain tumor trials: Beyond feasibility. Neuro-Oncology, 2022, , .	1.2	0
388	Microvessel density predicts behavior in pediatric optic pathway/hypothalamic gliomas. Journal of Clinical Oncology, 2004, 22, 1556-1556.	1.6	0
389	Abnormalities of Structural Brain Connectivity in Pediatric Brain Tumor Survivors. Neuro-Oncology Advances, 0, , .	0.7	0
390	GCT-04. Pattern of Treatment Failures in Central Nervous System Non-Germinomatous Germ Cell Tumors (CNS-NGGCT): A Pooled Analysis of Clinical Trials. Neuro-Oncology, 2022, 24, i54-i54.	1.2	0
391	LGG-41. The clinical and molecular landscape of gliomas in adolescents and young adults. Neuro-Oncology, 2022, 24, i97-i97.	1.2	0
392	MEDB-07. Long-term medical and functional outcomes of medulloblastoma survivors: a population-based, matched cohort study. Neuro-Oncology, 2022, 24, i105-i105.	1.2	0
393	MEDB-74. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Neuro-Oncology, 2022, 24, i123-i124.	1.2	0
394	MEDB-49. Relapsed SHH medulloblastomas in young children. Are there alternatives to full-dose craniospinal irradiation?. Neuro-Oncology, 2022, 24, i117-i117.	1.2	0
395	Long-term medical and functional outcomes of medulloblastoma survivors: A population-based, matched cohort study.. Journal of Clinical Oncology, 2022, 40, 10053-10053.	1.6	0
396	BRAF inhibitors in BRAFV600E mutated pediatric high-grade gliomas: upfront or at recurrence?. Neuro-Oncology, 0, , .	1.2	0

#	Article	IF	Citations
397	Long-term medical and functional outcomes of ependymoma survivors: A population-based, matched cohort study.. Journal of Clinical Oncology, 2022, 40, 10054-10054.	1.6	0